Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy

Abstract

BackgroundWorld Health Organization (WHO) guidelines for monitoring HIV-infected individuals taking combination antiretroviral therapy (cART) in resource-limited settings recommend using CD4+ T cell (CD4) count changes to monitor treatment effectiveness. In practice, however, falling CD4 counts are a consequence, rather than a cause, of virologic failure. Adherence lapses precede virologic failure and, unlike CD4 counts, data on adherence are immediately available to all clinics dispensing cART. However, the accuracy of adherence assessments for predicting future or detecting current virologic failure has not been determined. The goal of this study therefore was to determine the accuracy of adherence assessments for predicting and detecting virologic failure and to compare the accuracy of adherence-based monitoring approaches with approaches monitoring CD4 count changes.Methodology and FindingsWe conducted an observational cohort study among 1,982 of 4,984 (40%) HIV-infected adults initiating non-nucleoside reverse transcriptase inhibitor-based cART in the Aid for AIDS Disease Management Program, which serves nine countries in southern Africa. Pharmacy refill adherence was calculated as the number of months of cART claims submitted divided by the number of complete months between cART initiation and the last refill prior to the endpoint of interest, expressed as a percentage. The main outcome measure was virologic failure defined as a viral load > 1,000 copies/ml (1) at an initial assessment either 6 or 12 mo after cART initiation and (2) after a previous undetectable (i.e., < 400 copies/ml) viral load (breakthrough viremia). Adherence levels outperformed CD4 count changes when used to detect current virologic failure in the first year after cART initiation (area under the receiver operating characteristic [ROC] curves [AUC] were 0.79 and 0.68 [difference = 0.11; 95% CI 0.06 to 0.16; χ2 = 20.1] respectively at 6 mo, and 0.85 and 0.75 [difference = 0.10; 95% CI 0.05 to 0.14; χ2 = 20.2] respectively at 12 mo; p < 0.001 for both comparisons). When used to detect current breakthrough viremia, adherence and CD4 counts were equally accurate (AUCs of 0.68 versus 0.67, respectively [difference = 0.01; 95% CI −0.06 to 0.07]; χ2 = 0.1, p > 0.5). In addition, adherence levels assessed 3 mo prior to viral load assessments were as accurate for virologic failure occurring approximately 3 mo later as were CD4 count changes calculated from cART initiation to the actual time of the viral load assessments, indicating the potential utility of adherence assessments for predicting future, rather than simply detecting current, virologic failure. Moreover, combinations of CD4 count and adherence data appeared useful in identifying patients at very low risk of virologic failure.ConclusionsPharmacy refill adherence assessments were as accurate as CD4 counts for detecting current virologic failure in this cohort of patients on cART and have the potential to predict virologic failure before it occurs. Approaches to cART scale-up in resourc...

Neuropsychiatric and Socioeconomic Status Impact Antiretroviral Adherence and Mortality in Rural Zambia

“…Drug acquisition/pharmacy data provided the adherence estimates without recourse to viral load measurements to validate this adherence measure, but several studies have shown that pharmacybased data offer a reasonably valid proxy for assessing patient adherence. [38][39][40] The advent of free ARVs have led to discussion in the popular press about the problems of ARV adherence for people without sufficient access to food, 11, 12 but to our knowledge ours is the first study to provide quantitative, prospective data indicating that inadequate access to food may worsen adherence and increase mortality among people receiving ARVs. As evidenced by the baseline SES data acquired in this study, many people with HIV/AIDS in Zambia lack the resources needed for basic survival.…”

Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review

“…Details of the cohorts from the papers and conference abstracts are presented in Table 1 and Table 2 (available at: http://www.who.int/bulletin/ volumes/90/5/12-112946), respectively. Two reports 29,52 described outcomes from the same cohort but made use of two different thresholds to define viral suppression. A further seven repo rts 26,27,43,44,47,53,55 described outcomes using two or more thresholds of viral suppression.…”

Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with lipoatrophy, virological failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda

“…[22][23][24] We defined excellent, good and poor adherence as being punctual for >95%, 90-95% or <90% of the visits respectively. CD4 cell counts were measured at baseline and every six months after ART initiation.…”